A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
A clinical trial is a prospective experiment in which an investigator assigns an intervention (drug, device, behavioral strategy) to human subjects and measures the effect on a health outcome. The gold standard is the randomized controlled trial (RCT), which uses randomization to ensure treatment groups are comparable, blinding to prevent bias in assessment, and pre-specified endpoints to prevent data-driven hypothesis selection. Trials proceed through phases: Phase I (safety/dosing), Phase II (efficacy signals), and Phase III (confirmatory efficacy). Key design elements include the intention-to-treat principle (analyzing subjects by assigned group regardless of compliance), equipoise (genuine uncertainty about which treatment is better), and pre-registration of the analysis plan to prevent p-hacking.
Clinical trials are the most powerful tool for establishing whether a medical intervention works, because they combine the controlled comparison of an experiment with random assignment of treatments. From your study of study design, you know that observational studies — however well-conducted — can always be confounded by unmeasured variables. Randomization addresses this by ensuring that all patient characteristics, measured and unmeasured, are distributed approximately equally across treatment groups. Any observed difference in outcomes can then be attributed to the treatment rather than to baseline differences between groups.
The phases of clinical development reflect an increasing investment of resources matched to increasing confidence. Phase I trials enroll small numbers of healthy volunteers (or patients with no other options, in oncology) to establish safety, tolerability, and dosing. Phase II trials test the drug in patients with the target condition to assess preliminary efficacy and refine the dose. Phase III trials are the confirmatory step: large, randomized, usually multi-center studies designed to provide definitive evidence of efficacy. Only after a successful Phase III trial does a drug typically receive regulatory approval. Phase IV trials (post-marketing surveillance) monitor for rare adverse effects in broader populations after approval.
Blinding prevents bias in treatment administration and outcome assessment. In a double-blind trial, neither the patient nor the treating physician knows the assignment. This eliminates the placebo effect (patient expectations improving outcomes) and assessment bias (physicians interpreting ambiguous outcomes more favorably for the treatment they believe in). When blinding is impossible (surgical trials, behavioral interventions), blinded outcome assessment by independent evaluators provides partial protection.
The intention-to-treat (ITT) principle requires analyzing every randomized patient in the group to which they were assigned, regardless of whether they actually received or completed the treatment. This seems counterintuitive — why include patients who never took the drug? — but it preserves the randomization that makes the trial valid. Patients who discontinue treatment differ systematically from those who continue (they may be sicker, less motivated, or experiencing side effects). Excluding them creates selection bias that undoes the benefit of randomization. ITT estimates the real-world effect of a treatment policy ("offer this drug to patients") rather than the idealized effect ("give this drug to patients who tolerate it perfectly"), and the former is what clinicians and patients actually need to know.